CureVac in the news
mRNA medical technology development
Tamtam found 20 recent articles about CureVac.
- CureVac stock converts into BioNTech shares after merger
CureVac shares have converted to BioNTech shares following the acquisition, with BioNTech planning to close former CureVac sites, including the Tübingen headquarters, by the end of 2027.
- Nach Curevac-Aus in Tübingen: Was macht eigentlich die Curevac-Taskforce der Landesregierung?
A state task force formed after CureVac's exit from Tübingen is vaguely referencing future spin-off concepts and attempting to attract BioNTech founders.
- Morning Briefing: Biontech, Curevac – und die Bilanz des Staats als Unternehmer
The German government experienced a significant loss on its investment in CureVac, while BioNTech is scaling back operations, and the government is trying to block a Chinese acquisition of Zippel.
- Biontec schließt Curevac-Werk in Tübingen – Boris Palmer findet das "erschreckend"
Biontech is closing its former Curevac site in Tübingen and two other locations by early 2028, impacting 1800 employees, despite earlier promises to integrate the Tübingen research and production site.
- Palmer nennt BioNTech-Aus in Tübingen "erschreckend" - und bangt um Arbeitsplätze
BioNTech is closing three German production sites by 2028, including the former CureVac headquarters in Tübingen, due to decreased COVID-19 vaccine demand, impacting 1,800 jobs.
- Betriebsrat zu gescheiterten Verkaufsplänen: Für Curevac gibt es keine Hoffnung mehr
Curevac's planned sale fell through, leading to its definitive closure by the end of 2027.
- Biontech-Schließungen: Curevac-Kaufinteressenten erheben harte Vorwürfe
A US-led consortium interested in acquiring the former Curevac site accuses Biontech of not trying to save it.
- Licensable picture: Curevac in Tübingen
The image shows the CureVac site in Tübingen, which is part of the BioNTech Group.
- CureVac stock enters a new chapter after BioNTech takeover
BioNTech acquired CureVac in a $1.25 billion all-stock deal, integrating CureVac's mRNA assets into BioNTech's operations and potentially impacting up to 820 jobs.
- CureVac stock was delisted after its BioNTech merger
CureVac's stock was delisted following a merger with BioNTech, which is now reviewing divestment options for CureVac's operations and sites.
- Exklusiv: Bundesregierung will alle Biontech-Aktien, die der Bund hält, abstoßen
The German government intends to divest all its shares in Biontech, which it acquired after Biontech's takeover of Curevac.
- CureVac BV (CVAC) Stock Price Today: $4.66
CureVac develops mRNA vaccines and therapies for various diseases, with a focus on influenza, rabies, malaria, and oncology, after an initial COVID-19 vaccine attempt was discontinued.
- CureVac stock holds near USD 3 as pipeline focus continues
CureVac's stock is near USD 3.00 as investors assess declining revenues, increased net losses, and reduced cash reserves, focusing on pipeline progress and financial discipline.
- CureVac stock holds near its yearly range as pipeline data guide trading
CureVac's stock performance is primarily influenced by its pipeline development, clinical progress, and regulatory achievements rather than historical financial figures.
- Curevac in Tübingen: Übernahme durch Biontech und Standorte in Gefahr - Wirtschaft - SZ.de
CureVac, an mRNA pioneer, was acquired by BioNTech, leading to its decline.
- Die CureVac-Aktie reagiert auf Aktienzusammenlegung mit BioNTech-Anteil
CureVac's stock will undergo a consolidation on September 17, 2026, with shareholders receiving BioNTech shares, impacting its valuation while it continues mRNA development.
- CureVac stock stabilizes as investors eye mRNA pipeline and recent losses
CureVac's stock is trading steadily as investors await clinical trial results for its mRNA vaccine candidates, balancing pipeline potential against ongoing financial losses.
- Germany’s CureVac raises $213 million in IPO boosted by pandemic
CureVac, a German company, raised $213 million in an IPO boosted by the pandemic.
- Bayer, CureVac form alliance on COVID vaccine
Bayer and CureVac have formed an alliance to develop a COVID vaccine.
- BioNTech prüft Verkauf von CureVac
BioNTech is exploring the sale of its subsidiary CureVac by the end of September as part of a strategic shift to focus on cancer drug development.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like CureVac?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies